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Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in 
cancer cells and shows potent preclinical antitumor efficacy  
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Abstract 
Although Aurora A, B and C kinases share high sequence similarity, especially within the 
kinase domain, they function distinctly in cell cycle progression. Aurora A depletion primarily 
leads to mitotic spindle formation defects and consequently prometaphase arrest, while Aurora 
B/C inactivation primarily induces polyploidy from cytokinesis failure. Aurora B/C inactivation 
phenotypes are also epistatic to those of Aurora A, such that the concomitant inactivation of 
Aurora A and B, or all Aurora isoforms by non-isoform selective Aurora inhibitors, demonstrates 
the Aurora B/C dominant cytokinesis failure and polyploidy phenotypes. Several Aurora 
inhibitors are in clinical trials for T/B-cell lymphoma, multiple myeloma, leukemia, lung, and 
breast cancers. Here we describe an Aurora A-selective inhibitor, LY3295668, which potently 
inhibits Aurora autophosphorylation and its kinase activity in vitro and in vivo, persistently 
arrests cancer cells in mitosis, and induces more profound apoptosis than Aurora B or Aurora 
A/B dual inhibitors without Aurora B inhibition-associated cytokinesis failure and aneuploidy. 
LY3295668 inhibits the growth of a broad panel of cancer cell lines, including small cell lung 
and breast cancer cells. It demonstrates significant efficacy in small cell lung cancer (SCLC) 
xenograft and patient derived tumor (PDX) preclinical models as a single agent and in 
combination with standard-of-care agents. LY3295668, as a highly Aurora A selective inhibitor, 
may represent a preferred approach to the current pan-Aurora inhibitors as a cancer therapeutic 
agent.   
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Introduction  
The Aurora kinases are composed of three highly conserved serine/threonine kinases: 
Aurora A, B and C that regulate mitotic and meiotic processes (1-3).  The proteins contain a 
highly conserved central kinase domain with a variable N-terminal domain critical for unique 
protein-protein interactions, and a C-terminal domain carrying a protein stability regulation motif 
(4). 
Aurora A is critical to centrosome maturation/separation, mitotic spindle formation and 
mitotic spindle checkpoint activation (5-7). Aurora A mRNA/protein expression and kinase 
activity are cell cycle regulated, with basal level at interphase and expression/activity 
dramatically increased from late G2 to telophase in mitosis. The kinase activity requires Aurora 
A autophosphorylation at Thr288 in the activation loop. Aurora A associates with centrosomes at 
interphase cells, as well as with mitotic spindle in mitosis (8). Aurora A regulates mitotic 
progression by interacting with and phosphorylating multiple mitotic kinases, including 
Targeting Protein for Xklp2 (TPX2), p53, Large Tumor Suppressor Kinase 2 (LATS2), Rho-
associated, coiled-coil-containing protein kinase (p160ROCK), and others (8-11).  
Aurora B controls chromosome alignment in mitosis and cytokinesis as a catalytic unit in 
the chromosome passenger complex which also contains Survivin, Borealin, and INCENP (12-
14).  Similar to Aurora A, Aurora B expression and localization are cell cycle regulated, with 
expression and kinase activity peaking at mitosis and localization at kinetochores and 
centromeres from prophase to metaphase and then relocating to the cleavage furrow and 
midbody during cytokinesis. Meanwhile Aurora B kinase activity requires phosphorylation at 
Thr232 in the activation loop so that it can phosphorylate histone H3 at Ser10, and other 
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substrates for chromosome condensation and spindle checkpoint (13, 15). Aurora C expression is 
restricted to the testis, and functionally mimics Aurora B (16). 
Although the three Aurora kinases share high sequence similarity, especially at the kinase 
domain, they function distinctly in cell cycle progression (17).  Aurora A is a mitotic kinase 
whose depletion primarily leads to mitotic spindle formation defects and consequently 
prometaphase arrest in human cancer cell lines, evidenced by the increase of histone H3 Ser10 
phosphorylation as a mitotic marker. Aurora B/C function as chromosome passenger proteins 
such that kinase inactivation primarily induces polyploid cells.  This ploidy is caused by 
cytokinesis failure, as evidenced by the failure of daughter cell separation and the Aurora B-
mediated inhibition of histone Ser10 phosphorylation (18-20).  Aurora B/C inactivation 
phenotypes are also epistatic to these of Aurora A. Concomitant inactivation of Aurora A and B, 
or all Aurora isoforms, demonstrates the Aurora B/C dominant cytokinesis failure and 
polyploidy phenotypes. Polyploidy and subsequent chromosome segregation error-induced 
genomic instability are potential mechanisms of tumorigenesis and drug resistance. Thus, Aurora 
B/C inhibitory activity may counter the beneficial effects of Aurora A inhibition and should be 
avoided with a selective Aurora A inhibitor.  
Although more than a dozen of inhibitors have been developed, e.g. MLN8237 (alisertib), 
AZD1152 (barasertib), and others (21-25), most are either pan-Aurora or Aurora B/C inhibitors 
(26). As we show here, the most advanced Aurora inhibitor alisertib (MLN8237) has narrow 
Aurora A vs Aurora B selectivity, and at reported clinically efficacious concentrations (27), the 
Aurora B phenotype would dominate (27). Here we report development of a highly Aurora A 
selective kinase inhibitor, LY3295668, which potently inhibits proliferation in a broad panel of 
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cancer cell lines, induces apoptosis, and is highly efficacious in vivo, e.g., in SCLC and other 
xenograft and PDX preclinical tumor models. 
Materials and Methods 
Cell lines and antibodies NCI-H446, NCI-H69 (both from small cell lung carcinoma), HeLa 
(cervical adenocarcinoma), Calu6, NCI-H358 (both from lung carcinoma), and Detroit 562 
(pharyngeal carcinoma) were purchased from ATCC first in 2012 and later as needed. The panel 
of cell lines tested in Figure 4 is listed in the Supplementary Information. The cell lines were 
pathogen tested and authenticated by short tandem repeat (STR)-based DNA profiling. All cell 
lines were cultured in conditions recommended by vendors at 37°C with or without 5% CO2 in a 
humidified atmosphere and used within 2 months from thaw. Growth curves were determined for 
all cell lines. Cell densities were optimized to achieve robust cell growth during assays.  
The following antibodies against corresponding proteins were purchased and used 
according to the manufacturer’s instruction: -tubulin, Centrin 1 were from Abcam; actin, -
tubulin, Aurora A P-Thr288, Aurora B, P-AuroraA/B/C (P-Thr288/Thr232/Thr198, 
respectively), E-cadherin, vimentin, Sox2, cyclin B1, cleaved PARP and Histone H3 were from 
Cell Signaling; Histone H3 P-Ser10  was from EMD Millipore, Aurora A was from R&D 
Systems; -tubulin, actin and glyceraldehyde-3-phsophate dehydrogenase (GAPDH) were from 
Sigma and Aldrich; horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse 
immunoglobulin G (IgG) were from GE Healthcare; and goat anti-mouse IgM Alexa Fluor 488, 
anti-mouse-Alexa Fluor-647, anti-rabbit-Alexa Fluor-488, and Hoechst 33342 from Thermo 
Fisher Scientific. The immunofluorescence microscopy was done with Leica DMI6000B or Zeiss 
LSM880 microscopes. For quantification of P-AurA and P-H3 in mitotic cells, images were 
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acquired with the 40X water objective of an Opera Phenix and analyzed using Columbus 
software (Perkin Elmer, Waltham, MA).  
Test compounds LY3285668 was synthesized at Lilly Research Laboratories chemistry labs 
(Example 1 in ref. 28). MLN8237 (LI-R034) was purchased from Shanghai ChemPartner Co. 
Ltd.. AZD1152 (HM5015062) from Hutchison MediPharma Ltd., flavopiridol from 
AmFineCom, Inc. (Petersburg, VA). TGF was from R&D Systems (Minneapolis, MN) and 
SB431542 from Sigma-Aldrich (St. Louis, MO). All compounds were dissolved in DMSO as 10 
mM stock solution for in vitro assays. For in vivo animal studies, LY3295668 was formulated as 
a solution in 20% 2-hydroxypropyl-beta-cyclodextrin (HPBCD) in 25mM phosphate buffer pH 
2, adjusted with hydrochloric acid.  
Aurora A, Aurora B enzymatic and kinase profiling assays For details, see the 
Supplementary Information.  
Cell and tumor lysate preparations For details, see the Supplementary Information.  
Aurora A inhibition by Aurora A P-Thr288 MSD and Aurora B inhibition by Histone H3 
P-Ser10 inhibition (1 hour) high throughput cell-based assays For details, please see the 
Supplementary Information.  
Mitotic arrest phenotypic and cell proliferation inhibition by histone H3 P-Ser10 and DNA 
content multiplexing (24 hours) cell-based assay See the Supplementary Information and [40] 
for details. 
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Aurora A P-Thr288 and Aurora B histone H3 P-Ser10 in vivo target inhibition assays NCI-
H446 xenograft tumor lysates were used for in vivo target inhibition (IVTI). For details, see the 
Supplementary Information.  
Cell proliferation and apoptosis assays See supplementary Information. 
Epithelial to mesenchymal transition (EMT) and cancer cell stemness assays See 
Supplementary Information and (29). 
Antitumor growth efficacy with small cell lung cancer (SCLC) xenograft, PDX and other 
tumor models All in vivo studies were performed according to the Institutional Animal Care and 
Use Protocols of the party or provider conducting the experiments. NCI-H446, NCI-H69 and 
Detroit 562 xenograft and the small cell lung cancer (SCLC) patient‐derived tumor (PDX) 
models (in Oncotest GmbH, Charles River Laboratories, Freiburg, Germany) were used. For 
details, see Supplementary Information. 
Western blot and Immunofluorescence analysis See Supplementary Information.  
Flow Cytometry See Supplementary Information. 
Results  
LY3295668 is a potent Aurora A selective inhibitor 
LY3295668 ((2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6- [(5-methyl-
IH-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methylpiperidine-4-carboxylic acid) was identified 
during a medicinal chemistry program seeking to discover highly selective inhibitors of Aurora 
A kinase (Fig. 1A) (28). It is a reversible ATP competitive inhibitor with high aqueous solubility 
at 1.89 mg/ml. It also shows excellent physiochemical properties with LogD (pH7.4) of 2.38 and 
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measured fraction unbound of 1.0%, 1.1%, 1.4%, and 4.5% in human, dog, rat, and mouse sera, 
respectively.  
LY3295668 potently inhibited Aurora A and showed excellent kinase selectivity in 
binding of a panel of 489 protein kinases in vitro, and carries significant binding activity for only 
3 other protein kinases with IC50s less than 0.1 μmol/L (Fig. 1B). Enzymatically LY3295668 
showed remarkable selectivity against Aurora B (1,339-fold. Fig. 1C left). In NCI-H446 cells, 
LY3295668 was a potent (IC50 = 0.00059 mol/L) inhibitor on Aurora A kinase 
autophosphorylation at Thr288 (Fig. 1C mid).  Aurora B inhibition potency, as determined by 
histone H3 Ser10 phosphorylation, was very poor (IC50 = 1.42 mol/L) (Fig. 1C middle), 
indicating a >2,000-fold selectivity of Aurora A over Aurora B in this cell-based assay. 
Consistent with LY3295668 Aurora A inhibitory activity, 24 hours treatment led to an increase 
in histone H3 Ser10 phosphorylation (mitotic arrest) as well as in G2/M DNA content (Fig. 1C 
right) in HeLa cells. Accordingly, NCI-H446 and HeLa cell proliferations were inhibited (Fig. 
1C right and Supplementary table 1). The correlation of Aurora A biochemical IC50 with P-H3 
elevation, 4N DNA content increase, and cell proliferation inhibition indicates that LY3295668 
Aurora A inhibition leads to mitotic arrest as well as cell proliferation inhibition.  
Using a chemoproteomics platform (KiNativ) (30) to detect the compound kinase binding 
profile in NCI-H446 cancer cells, LY3295668 treatment at 1 μmol/L for 24 hours demonstrated 
an excellent Aurora A potency with inhibition efficiency at 98%, as well as kinase selectivity 
with only one other kinase (EphA2) showing significant inhibition (92%) among 203 kinases 
tested (Supplementary table 2). Under this condition, PLK1, Aurora B and EGFR kinase binding 
increased 256%, 265% and 851% (n=2), respectively. Both PLK1 and Aurora B expression are 
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cell cycle regulated, and it is expected that they would increase dramatically in mitosis 
(Supplementary table 2), indicating LY3295668 treatment induces G2/M arrest. 
We further used the KiNativ chemoproteomics platform to examine the LY3295668 
kinase inhibition profile in vivo with the NCI-H446 xenograft model. When the animals were 
treated at 50 mg/kg once-a-day (QD) for 3 hours, only Aurora A and Aurora B showed evidence 
of significant inhibition out of 195 kinases detectable (Supplementary Fig. S1A left. 
Supplementary Table 3). When mice were treated with LY3295668 at 50 mg/kg twice-a-day 
(BID) (at 0 and 12 hours) and then tumors collected at 24 hours, the compound only inhibited 
Aurora A significantly, while PLK1, AURKB, and three other kinase expression increased 
significantly (Supplementary Fig. S1A right), again indicating LY3295668 treatment in vivo led 
to Aurora A inhibition-induced mitotic arrest. In the mouse spleen, LY3295668 treatment at 50 
mg/kg QD for 3 hours only significantly inhibited Aurora A (Supplementary Fig. S1B. 
Supplementary Table 4).  Two treatments of LY3295668 (50 mg/kg BID, at 0 and 12 hours) 
demonstrated again Aurora A is the only kinase significantly inhibited and a Serine/Threonine-
Protein Kinase A-Raf is the only kinase with expression significantly increased (Supplementary 
table 4). Taken together, LY3295668 consistently demonstrates selective Aurora A inhibition in 
vitro and in vivo. 
Several different Aurora A and Aurora B kinase substrates in cells have been identified 
and used to characterize Aurora kinase inhibitors (26). Here we are the first to use an Aurora A 
P-Thr288 inhibition assay to screen for an Aurora A selective inhibitor. Pairwise analysis from 
2940 compounds from our structure-activity relationship (SAR) library indicates that Aurora A 
cell-based P-T288 inhibition is most highly correlated with Aurora A enzymatic assay not 
Aurora B (Spearman’s ρ = 0.7264; Supplementary Table S5). The more revealing correlation 
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comes from multiple linear regression analysis. For Aurora A cell assay (Fig. 1D left), improving 
Aurora A biochemical potency 10-fold (1 log unit) would have an expected improvement 10 fold 
(Log Aurora A has Estimate of 10
1.083
) in Aurora A cell potency, while Aurora B biochemical 
10-fold improvement can only contribute 1.6 fold (Log Aurora B has Estimate of 10
0.202
). For 
Aurora B cell-based activity (Fig. 1D mid), Aurora A enzymatic activity potency increase does 
not contribute at all (10
-0.043
), while 10 fold Aurora B enzymatic potency increase contributes to 
5 fold increase in the Aurora B cell potency (10
0.639
). So both pairwise and multiple regression 
correlation analyses support our flowscheme to identify Aurora A selective inhibitors (Fig. 1D 
and Supplementary Table S5).  
Aurora A and B inhibition are not equal in inducing mitotic arrest (Fig. 1D right):  
improving Aurora A biochemical potency 10-fold contributes to mitotic arrest 2.9 fold (10
0.457
) 
while Aurora B only 1.9 folds (10
0.268
). The data indicates that Aurora A inhibition was much 
more effective in mitotic arrest induction, while Aurora B inhibition induced endoreduplication 
and polyploidy phenotype may interfere with the mitotic arrest phenotype.  
To determine the Aurora A inhibition potency required inducing significant cell 
proliferation inhibition and thus significant anti-tumor efficacy in vitro and in vivo, a statistical 
analysis was performed which indicates that 90% Aurora A inhibition (Aurora A P-T288 IC90) 
can effectively induce cell proliferation inhibition as well as mitotic arrest (Supplementary Fig. 
S2). 
Aurora A selective inhibition by LY3295668 produces mitotic arrest and apoptosis in 
cancer cells. 
on January 20, 2021. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 17, 2019; DOI: 10.1158/1535-7163.MCT-18-0529 
The potency and selectivity of LY3295668 against Aurora A translated to mitotic arrest 
measured by histone H3 P-Ser10 marker and an increase in 4N DNA content in HeLa, NCI-
H446, Calu6 and other tumor cell lines (Fig. 1B, Fig. 2A left and Supplementary Fig. S3). 
Several Aurora inhibitors are being tested clinically, notably alisertib (MLN8237) and barasertib 
(AZD1152) (21-23, 25). Each of these Aurora inhibitors was compared to LY3295668 in cell-
based assays (Fig. 2). Alisertib is an Aurora A/B dual inhibitor with approximately 16-fold 
Aurora A selectivity vs. Aurora B in cell-based assay (Fig. 2A mid). While mitotic arrest from 
LY3295668 treatment was still evident up to 20 μmol/L (the highest tested concentration), 
alisertib only showed Aurora A selective inhibition between 0.05 to 0.25 μmol/L, but exhibited 
Aurora B-related P-H3 inhibition at concentrations above 0.25 μmol/L (Fig. 2A middle). 
Barasertib also demonstrated an Aurora B selective inhibitor dominated phenotype (Fig. 2A 
right).  
All three Aurora inhibitors potently inhibited HeLa cell proliferation (Fig. 2B, left). 
LY3295668 also demonstrated potent apoptosis induction with significant Caspase 3/7 increase 
reaching maximal at 0.087 μmol/L and higher (Fig. 2B right), correlating to its Aurora A 
inhibition, mitotic arrest, and cell proliferation inhibition potency (Fig. 2A left). In contrast, 
alisertib showed most dramatic apoptosis induction only from 0.087 to 0.250 μmol/L, matching 
its Aurora A selective cell activity range (Fig. 2A middle). At concentrations of Alisertib shown 
to be dominated by effects of Aurora B inhibition (>0.25 mol/L), the apoptosis induction 
actually slightly decreased (Fig. 2B right). Barasertib did not induce considerable apoptosis, 
reflected by less CASP3/7 induction (Fig. 2B right).  
The cell growth inhibition and apoptosis induction difference among LY3295668 and 
other Aurora inhibitors (2.2 mol/L) can also be observed from cell morphology images 
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(Supplementary Fig. S4) taken from the same cell culture plates used for Incucyte quantitation in 
Fig. 2B.  The majority (96.4%) of HeLa cells were killed by LY3295668 showing CASP3/7 
positivity (green dots).  However, there were still significant numbers of surviving cells showing 
enlarged/multi-nuclei and cytoplasm in alisertib or barasertib treatment, indicating they had gone 
through endo-reduplication and cytokinesis failure mediated by Aurora B inhibition 
(Supplementary Fig. S4).   
Immunofluorescent staining of HeLa cells treated with 1 mol/L of LY3295668 clearly 
indicates mitotic arrest at prometaphase with abnormally shortened microtubule spindle network, 
disorganized arrays of microtubules (-tubulin staining and Aurora A staining, which localizes to 
mitotic spindle and centrosomes), as well as misaligned condensed chromosomes (DAPI 
staining) (Fig. 3A upper and mid). LY3295668 treatment also inhibited Aurora A P-Thr288 (P-
AurA) staining at 94% (±0.468), with only a minor effect on histone H3 P-Ser10 (P-H3, 
16%±0.2093), consistent with its Aurora A selective inhibition (Fig. 3A upper and mid. Fig. 3B). 
Alisertib treatment also arrested cells in mitosis with disarrayed microtubule spindle and 
misaligned chromosomes, but abolished both Aurora A P-Thr288 (95%±0.433) and histone H3 
P-Ser10 (93%±0.313) staining. This is indicative of an Aurora A/B dual inhibition phenotype 
(Fig. 3A upper and mid. Fig. 3B). Although the gross network of mitotic spindle was near 
normal, barasertib treatment led to misaligned chromosomes as well as corrupted mitotic spindle 
(Fig. 3A upper and mid). Barasertib inhibited histone H3 P-Ser10 (90%±4.054), but only 
marginally on Aurora A P-Thr288 (21%±2.976), representative of an Aurora B dominant 
phenotype (Fig. 3A upper and mid. Fig. 3B).  
PLK4 inhibition was also observed with LY3295668 (Fig. 1C) and can produce mitotic 
arrest. To distinguish between the Aurora A vs PLK4 inhibition-induced mitotic phenotype, cells 
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were stained with Centrin 1 since centriole duplication is PLK4 dependent (31). Neither 
LY3295668, nor alisertib or barasertib perturbed centriole duplication and maturation with 
duplicated Centrin staining localized at the center of centrosomes in all the mitotic cells (Fig. 3A 
bottom). The data indicates that although LY3295668 may inhibit PLK4 enzyme activity in 
vitro, this activity did not translate into significant inhibition of PLK4 in cells (Fig. 3A bottom). 
Western blot analysis further revealed the Aurora A vs Aurora B inhibition difference on 
mitotic arrest and apoptosis (Fig. 3C). At 0.25, 1 and 5 mol/L, LY3295668 treated cells for 24 
hours showed Aurora A, Aurora B, histone H3 P-Ser10, and cyclin B1 increases in a dose-
dependent manner, indicating it effectively induced mitotic arrest (Fig. 3C left). While there was 
a transient increase in the expression of these endpoints by alisertib at 0.25 mol/L (Aurora A 
inhibition), the increases were quickly lost due to transition to an Aurora B inhibition dominant 
phenotype at concentrations >0.25 mol/L.  Cyclin B1 levels decreased from those at 0.25 
mol/L to those at 1 and 5 mol/L correlated with its cytokinesis defects with Aurora B 
inhibition, since cyclin B1 degradation is cell cycle regulated toward telophase and cytokinesis. 
Barasertib as an Aurora B selective inhibitor did not show these target gene expression increase, 
and quite that opposite, it induced histone H3 P-Ser10 decrease from its potent Aurora B kinase 
inhibition (Fig 3C left). LY3295668 exhibited dose-dependent PARP cleavage (apoptosis 
induction) across the concentration range tested (0.25 to 5 mol/L), while alisertib induced 
apoptosis dose-dependently up to 0.25 mol/L (most Aurora A selective concentration) which 
then decreased at 1 and 5 mol/L (Aurora B inhibition), and barasertib only induced moderately 
(Fig. 3C). Longer treatment for 48 hours showed similar trend (Fig. 3C right). 
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Several recent studies show Aurora A functions in EMT and tumor stemness (32-34). We 
tested whether LY3295668 could also prevent EMT and reduce cancer stemness in a validated 
model cell line, NCI-H358 (29). As previously demonstrated, TGF inhibitor SB431542 reversed 
the TGF-induced epithelial marker E-cadherin decrease (Fig. 3D). LY3295668, but not alisertib 
or barasertib, was able to partially prevent the TGF induced E-cadherin decrease at 0.1 mol/L 
(Fig. 3D). Mesenchymal marker vimentin also showed a similar trend as seen with E-cadherin, 
albeit to a lesser degree (Supplementary Fig. S5). LY3295668 and alisertib inhibited Sox2 
expression at the same concentration (Fig. 3D), indicating Aurora A inhibitors can reduce cancer 
cell stemness. However, Aurora B inhibitor barasertib did not cause a significant Sox2 decrease 
at the same concentration (Fig. 3D). 
The Aurora A vs Aurora B selectivity of these compounds also impacted genomic 
stability as determined by flow cytometry analysis (Fig. 3E). LY3295668 induced strong G2/M 
arrest after 24 hours in HeLa cells (4N peak). The mitotic arrest persisted up to 48 hours without 
significant progression to 8N DNA content (tetraploid from the second round of genome 
replication). Although both alisertib and barasertib initially caused mitotic arrest by 24 hours 
treatment, they accumulated tetraploid (8N) cells after 48 hours treatment (two doublings for 
HeLa cells) through endo-reduplication and cytokinesis failure; a profile attributed to Aurora B 
inhibition. These polyploid cells can survive multiple rounds of endo-reduplication without fully 
engaging apoptosis or other cell death pathway activation, which explains the surviving cells in 
Supplementary Fig. S4.  
LY3295668 inhibits SCLC and breast cancer cell viability 
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LY3295668 showed significant inhibition of cancer cell viability across a panel of 80 
tumor lines (Fig. 4), mostly from breast and lung cancers. The potency of LY3295668 in cell 
lines ranged from IC50 single-digit nmol/L to greater than 20 mol/L (Fig. 4A). 55 out of 80 
(68%) cell lines displayed significant sensitivity (IC50 < 1 mol/L) to LY3295668 with an 
average IC50 of 0.048 mol/L (Fig. 4A). 28/34 (82%) of breast, as well as 18/27 (67%) of lung 
cancer cell lines, are sensitive to LY3295668 treatment and have IC50s below 1 mol/L. The 
average IC50s were 0.039 and 0.034 mol/L, respectively, for the sensitive breast and lung panels 
(Fig. 4B and 4C). In breast cancer cells, triple negative breast cancer (TNBC) was the most 
sensitive subtype with average IC50 0.164 mol/L, and 13/15 (87%) lines had IC50 below 1 
mol/L, while luminal was the most insensitive with an average IC50 3.653 mol/L and 13/19 
(68%) had IC50 less than 1 mol/L (Fig. 4B). In lung cancer cells, small cell lung cancer (SCLC) 
was the most sensitive tumor type with an average IC50 of 0.016 mol/L and all 6 (100%) SCLC 
cell lines were sensitive to LY3295668 (Fig. 4C). 12/21 (57%) of NSCLC were sensitive to 
LY3295668 with an average IC50 of 4.694 mol/L (Fig. 4C).  
A series of 10 compounds with Aurora A and/or Aurora B activity were tested in a bone 
marrow colony formation assay to better understand the heme toxicity relative Aurora kinase 
selectivity.  LY3295668 showed an IC90 of 1.4 mol/ml, while alisertib and barasertib gave IC90s 
at 0.2 and 0.1 mol/ml, respectively. Multiple regression analysis indicates that human bone 
marrow cell inhibition was correlation with Aurora B cell potency, but not Aurora A 
(Supplementary Fig. S6).  This would suggest that the heme toxicity observed in rodents and 
clinically (alisertib, barasertib) may be driven by the Aurora B activity.  As such, an Aurora A 
selective inhibitor might be better tolerated (also see 43). 
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LY3295668 is a very potent Aurora A inhibitor in vivo.  
LY3295668 demonstrated potent Aurora A inhibition in vivo in the NCI-H446 xenograft 
model using nude mouse and rat (Fig. 5A) at 3 hours after oral dosing. At 30 mg/kg oral dosing 
in mice, LY3295668 also showed persistent Aurora A target inhibition (>90% P-Aurora A 
inhibition) for more than 8 hours and induced significant mitotic arrest as indicated by increases 
in mitotic maker histone H3 Ser10 phosphorylation (Fig. 5B left). At 50 mg/kg, LY3295668 
effectively inhibited Aurora A >90% for 12 hours (96.0, 95.1, 94.5, 90.7, and 77.5% at 1, 4, 8, 
12, and 24 hours, respectively). Correspondingly, mitotic arrest persisted up to 16 hours post-
dosing with histone H3 P-Ser10 increasing by 237, 323, 330, 245, and 328% at 1, 4, 8, 12, and 
24 hours, respectively. LY3295668 has a calculated Threshold Effective Dose (TED50: dose that 
produces an effect equal to 50% P-AurA inhibition) at 2.13 mg/kg and Threshold Effective 
Concentration (TEC50: concentration that produces an effect equal to 50% P-AurA inhibition) of 
0.07 mol/L. We estimated that with twice daily (BID) dosing schedule, a dose of 30 mg/kg 
might be expected to achieve >90% Aurora A target inhibition for more than 16 hours daily, 
while a dose of 50 mg/kg would achieve this level of target engagement for the entire dosing 
period. At exposures comparable to those in the mouse, a 5 mg/kg oral dose in rats, LY3295668 
showed persistent Aurora A target inhibition and a corresponding histone H3 P-Ser10 increase 
(Fig. 5B, right). 
LY3295668 at these doses did not inhibit histone H3 P-Ser10 at the 1-hour time point 
(Fig. 5B), indicating it did not show Aurora B inhibition in xenograft tumors. Taken together 
with the previous kinase profiling data (Fig. 1 and Supplementary Fig. S1), LY3295668 
consistently demonstrated that it is a potent and selective Aurora A inhibitor in vivo. 
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LY3295668 demonstrates potent and durable responses in preclinical tumor models  
Inhibition of cell proliferation inhibition by LY3295668 was time-dependent, i.e.  
potency increased with longer incubation time (4 to 48 hours) and maximal inhibition reached 
after 24-48 hours (Supplementary Table S1 and Fig. S7). After 48 hours of LY3295668 
treatment, proliferation IC50s were 0.090 ± 0.021 (n=2), 0.108 ± 0.034 (n=2), and 0.076 ± 0.033 
(n=2) μmol/L, respectively, in NCI-H446, HeLa and Calu6 cells (Supplementary Table S1). The 
time-dependent cell proliferation inhibition in combination with the notion that 90% phospho-
Aurora A inhibition was needed (Supplementary Fig. S2) enabled us to design an optimized in 
vivo efficacy schedule. We subsequently conducted in vivo efficacy studies by achieving >90% 
phospho-Aurora A inhibition for at least 16 hours/day (30 mg/kg) or 24 hours/day (50 mg/kg) in 
mice (Fig. 6A and B).  
LY3295668 demonstrated significant tumor growth inhibition in SCLC NCI-H446 
xenograft mode in a dose-dependent manner (Fig. 6A left).  Tumors treated with 30 mg/kg 
LY3295668 regrew once dosing had stopped, while the tumors receiving 50 mg/kg LY3295668 
did not show significant re-growth until 14 days post dosing (day-55 total duration, Fig. 6A left). 
LY3295668 was well tolerated, with no significant body weight loss in the study. 
We varied dosing schedule to understand the duration of LY3295668 dosing needed to 
reach durable efficacy in SCLC NCI-H69 xenograft model. LY3295668 at 50 mg/kg, dosed 
either as (BIDx7, rest 14) x 2, (BIDx14, rest 7) x 2, or (BIDx21) x 2 schedules, all produced 
significant tumor growth inhibition (Fig. 6A mid). Although the effect of (BIDx7, rest 14) 
schedule did not persist after dosing stopped, both (BID14, rest 7) and BIDx21 dosing schedules 
similarly produced sustained tumor growth inhibition; lasting more than 40 days (109-day total 
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duration) post-dosing (Fig. 6A middle). We also tested comparable daily dose scenarios by 
dosing LY3295668 at 90 mg/kg BIDx7, 50 mg/kg BIDx14, or 30 mg/kg BIDx21 (Fig. 6A right). 
The results confirmed that constant, complete target inhibition (50 mg/kg BIDx14) produced the 
most robust anti-tumor efficacy (Fig. 6A right) that persisted for at least 40 days post-dosing 
(day-80 total duration). Should a dosing holiday be required, LY3295668 administered at 
concentrations achieving >90% Aurora A inhibition on a 14-day-on/7-day-off schedule would 
still be expected to reach maximal efficacy in SCLC (Fig. 6A). 
We further demonstrated LY3295668 anti-tumor efficacy using SCLC Patient-Derived 
Xenografts (PDX) models. In LXFS538, LY3295668 treatment induced 61.1% of tumor 
regression at day-56 of treatment while the standard-of care (Etoposide + Cisplatin) was only 
moderate at 43.1% tumor growth inhibition (Fig. 6B left). When there was a significant tumor re-
growth from one of the 5 tumors at day-70, LY3295668 re-treatment at 50 mg/kg showed tumor 
regression again (Fig. 6B left). In LXFS2156, LY3295668 treatment at 50 mg/kg BIDx28 
showed 97.2% of tumor growth inhibition while the standard-of-care did not show any 
significant tumor inhibition (Fig. 6B right).  However, the tumor inhibition in LY3295668 
treated group did not persist beyond dosing period (Fig. 6B right).  
Efficacy of LY3295668 was also explored in combination with various standards of care. 
In LXFS2156, LY3295668 at 40 mg/kg showed significant efficacy, while SoC (Etoposide + 
Cisplatin) did not significantly affect tumor growth (Fig. 6C left). LY3295668 in combination 
with SoC produced better-than-additive effect than either monotherapy (Fig. 6C left). In 
LXFS573, LY3295668 also showed significant combination benefit with SoC agents (Fig. 6C 
mid). In these studies, 10-15% of body weight losses were observed in combination groups.  
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Multiple lines of data indicate potential synergism between Aurora A and EGFR 
inhibitors (35). Consequently, LY3295668 was investigated for potential synergy in combination 
with cetuximab and cisplatin in a Head and Neck squamous cell carcinoma (HNSCC), the 
Detroit 562 xenograft model (Fig. 6C right). At the end of dosing period (day-44 total duration; 
4-day post dosing regimen completed), LY3295668 at 30 mg/kg alone showed significant tumor 
growth inhibition, so did cetuximab or cetuximab plus cisplatin treatment. More importantly, 
LY3295668 in combination with cetuximab or with both cetuximab plus cisplatin exhibited a 
synergistic effect in comparison to either monotherapy, produced much prolonged tumor growth 
inhibition beyond the dosing period, especially LY3295668 with cetuximab + cisplatin group 
(Fig. 6C right). 
Discussion 
Although Aurora kinases A, B and C are highly homologous, they are not functional 
orthologues. Aurora A-selective inhibition leads to mitotic arrest in many cancer cells. The 
mitotic arrest often further progresses to cancer cell apoptosis/death in sensitive cancer cell lines.  
We contend that an Aurora A-selective inhibitor such as LY3295668 may be more effective than 
Aurora B or Aurora A/B dual inhibitors (alisertib, barasertib), as it would avoid DNA endo-
reduplication and polyploidy, which could persist for multiple cell divisions without completely 
killing the cancer cells (36). A couple of Aurora A inhibitors have been identified over the years, 
however, they suffer either the lack of Aurora A inhibition potency or lack of enough selectivity 
against Aurora B (Fig. 2, and (24, 26)). LY3295668 is a potential best-in-class Aurora A 
inhibitor with >1,000-fold Aurora A vs Aurora B selectivity.  Furthermore, we contend that at 
the pharmacologically relevant concentrations, LY3295668 only inhibits Aurora A in vitro and 
in vivo, not Aurora B.  
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Using LY3295668, we discovered that Aurora A vs Aurora B/C inhibitors show profound 
differences in mitotic arrest phenotypes and especially apoptosis induction. While LY3295668, 
alisertib and barasertib each can potently inhibit HeLa cell growth, only LY3295668 consistently 
promoted apoptosis across the range of tested concentrations, as well as inhibits EMT and cancer 
cell stemness markers (Fig. 2 and 3). Interestingly, alisertib inhibits Aurora A-selectively in a 
range of 0.080-0.250 mol/L. This corresponds to the same range of concentrations needed to 
induce maximal apoptosis in HeLa cells. At concentrations >0.25 mol/L, alisertib reduced its 
apoptosis induction capacity as it switched to an Aurora B-dominant phenotype (Fig. 2 and 3). 
So at a clinically relevant human plasma exposure of 1 to 2 mol/L (37-40), alisertib behaves 
phenotypically as an Aurora B inhibitor in vivo (41). This phenotype has been observed 
previously in sarcoma cells, although alisertib showed an Aurora A inhibition phenotype 
(increased phospho-H3) in their model (41). While alisertib is a dual Aurora A/B inhibitor in 
vitro, the appearance of the Aurora B phenotype is exposure-dependent, ie., at lower plasma 
concentrations, only Aura A may be inhibited. 
Aurora B inhibition-induced endo-reduplication and subsequent polyploidy are 
retinoblastoma protein-dependent and can lead to chromosome segregation errors and thus 
genomic instability through aberrant mitosis (Fig. 2 and 3) (17, 18, 23, 26, 42, 43). As such, 
Aurora B inhibitor-induced tetraploid cells, which show better survival after compound treatment 
(Fig. 2 and 3), could significantly increase the refractory/resistant cell population, especially 
when the inhibitor in vivo exposure is at sub-threshold levels during dosing intervals.  
Aneuploidy/Genomic instability is one of the most prevalent signatures of cancer (44, 45). 
Polyploidy, including tetraploidy, is thought to be a major pathway to induce aneuploidy and 
genomic instability. For example, RAS oncogene induces tetraploidy as an intermediate step in 
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its tumorigenesis (46). As for cancer therapy, Aurora A selective inhibitor may be the best 
strategy and Aurora B activity should be avoided. LY3295668 has now advanced to Phase I 
clinical testing to test the translation of this hypothesis in patients (NCT03092934). 
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Figure legends 
Figure 1. LY3295668 is a potent and highly selective Aurora A inhibitor. A: LY3295668 
chemical structure. B: Kinase binding profile from DiscoverX. All kinases with IC
50
 less than 1 
μmol/L are listed. C: LY3295668 dose response curves on Aurora A, Aurora B enzymatic (left), 
cell (middle) inhibitions and mitotic phenotypic (right) profile. Enzymatically, AurA inhibition 
IC
50
 0.00112± 0.000148 mol/L (n=4, ■); AurB IC
50
 1.51± 0.668 mol/L (n=5, ○).  In cells, 
AurA inhibition IC
50
 0.00059± 0.000784 mol/L (n=4, ■); IC
90
 of 0.00623± 0.00318 mol/L 
(n=4, ■); and AurB inhibition IC
50
 1.42± 0.416 mol/L (n=4, ○). Mitotic index (MI) (P-H3 
increase) IC
50
 0.108±0.015 mol/L (n=4, ■ on left Y-axis); G2/M arrest (4N DNA content 
increase) IC
50
 0.108± 0.027 mol/L (n=4, Δ on left Y-axis); and cell growth inhibition IC
50
 
0.053± 0.012 mol/L (n=4, ○ on right Y-axis).  D: Multiple regression analysis for Aurora A 
(left), B (middle) and mitotic arrest (right) cell phenotype potency (on 448, 435, and 627 SAR 
cpds with available data points, respectively) with Aurora A and B enzymatic activity correlation. 
Figure 2. LY3295668 selective Aurora A inhibition leads to most significant apoptosis in HeLa 
cells.  A: In comparison of alisertib and barasertib, LY3295668 showed the most persistent 
Aurora A inhibition induced mitotic arrest. LY3295668 cell potency is listed in Fig. 1C (middle 
panel). Alisertib showed AurA cell IC
50
 0.004±0.004 mol/L (n=5); AurB cell IC
50
 0.051±0.010 
mol/L (n=7); and Mitotic index (MI) (P-H3 increase) IC
50
 0.066±0.039  mol/L (n=7). 
Barasertib exhibited AurA cell IC50 >20 mol/L; AurB cell IC
50
 0.011±0.006 mol/L (n=11); 
and Mitotic index (MI) (P-H3 increase) IC
50
 0.022±0.007 mol/L (n=4). B: LY3295668, alisertib 
and barasertib cell proliferation inhibition (left) and apoptosis induction (CASP3/7, right) in 
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Incucyte assay. Each square represents the cell confluency or the CASP3/7 positive green dot 
numbers (Y-axis) in the cell culture well from 0 to 48-hour (X-axis). The percentage of cell 
growth or apoptosis positive cell numbers is plotted below. 
Figure 3. LY3295668 Aurora A inhibition induced mitotic arrest leads to apoptosis, not 
polyploidy. A: Immunofluorescent staining on mitotic spindle (-tubulin), Aurora A, Aurora P-
Thr288, histone H3 P-Ser10, and Centrin 1 localization on Hela cells treated with 1 mol/L of 
LY3295668, alisertib, or barasertib for 24 hours. B: Quantification of P-Aurora A and P-H3 
inhibition by the Aurora inhibitors from 3 repeated immunofluorescence experiments. Statistical 
significance is indicated by *** (p<0.001). C: Western on mitotic and apoptosis markers with 
HeLa cells treated by indicated Aurora inhibitors for 24 (left) and 48 (right) hours. D: Western on 
mesenchymal marker E-cadherin and stemness marker Sox2 in NCI-H358 cells. E: DNA 
histogram by flow cytometry on mitotic arrest and tetraploidy induction from indicated Aurora 
inhibitor treatment. HeLa cells were treated with 1 mol/L of each compound for 24 (upper 
panel) or 48 (lower panel) hours. 
Figure 4. LY3295668 shows potent cell viability inhibition in a large panel of cancer cells.  A: 
Waterfall plot of LY3295668 cell viability inhibition potency Log(IC50). The cell lines are 
indicated at the bottom of the plot. B: LY3295668 cell viability inhibition potency Log(IC50) in 
breast cancer cell line sub-panel. C: LY3295668 Log(IC50) in lung cancer cell line sub-panel. The 
cells at exponent growth phase were treated with LY3295668 for two doubling time and the cell 
viability inhibition was measured by CellTiter Glo (CTG) assay.  
Figure 5. LY3295668 inhibits Aurora A in vivo.  A: In mouse and rat NCI-H446 xenograft 
models, animals were treated with LY3295668 at indicated doses for 3 hours. Aurora A P-Thr288 
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inhibition in tumors (■ Y-axis at left) and compound exposure in animal plasma (○ Y-axis on 
right) were measured. B: Animals were treated with LY3295668 once. At indicated time points, 
tumor and plasma samples were collected for Aurora A P-Thr288, P-H3 (■ and ○, Y-axis on left), 
and compound exposure (□ Y-axis on right). TED
50
: Threshold Effective Dose (dose that 
produces an effect that equals to 50% P-Aurora A inhibition). TEC
50
: Threshold Effective 
Concentration (plasma concentration that produces an effect that equals to 50% P-Aurora A 
inhibition).  
Figure 6. LY3295668 is efficacious in preclinical tumor models. A: LY3295668 was dosed at 
indicated doses and durations with NCI-H446 (left) and NCI-H69 (middle and right) models. 
The dosing durations for each treatment is indicated by the red line (left) and lines color coded to 
match the dosing schedules (middle and right). At the indicated time (red arrow), the average 
tumor growth inhibitions for each treatment group are plotted in the insert. B: LY3295668 
efficacy with SCLC PDX models. LY3295668 was dosed at 50 mg/kg by oral (P.O.) BID for 28 
days, while the Standard-of-Care was dosed with etoposide 30 mg/kg subcutaneously (S.C.) 
Q7Dx4 plus cisplatin 3.2 mg/kg S.C. Q7Dx4. The dosing duration is indicated by the red line. C: 
LY3295668 in combination with SoC showed better efficacy in SCLC PDX and Head and Neck 
xenograft models. For LXFS 2156 and 573 SCLC PDX models, LY3295668 was dosed at 40 
mg/kg P.O. for 28 days. SoC was etoposide at 30 mg/kg S.C. Q7Dx3 plus cisplatin 3.2 mg/kg 
S.C. Q7Dx3. For Detroit 562 xenograft model, LY3295668 was dose at 30 mg/kg P.O. BID for 
28 days. Cisplatin was used at 4 mg/kg Q7Dx4 and cetuximab was at 20 mg/kg twice-a-week 
(BIW)x4. The dosing duration is indicated by the red line.The insert plot of tumor response rates 
at the measured time point are indicated by the red arrow, and the statistical significance is 
indicated by the p value. 
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Term Estimate SE P > ItI 
Intercept 1.347 0.203 < 0.0001 
Log Aurora A 1.083 0.083 < 0.0001 
Log Aurora B 0.202 0.092 0.0009 
Term Estimate SE P > ItI 
Intercept 0.408 0.063 < 0.0001 
Log Aurora A -0.043 0.028 0.1241 
Log Aurora B 0.639 0.026 < 0.0001 
Term Estimate SE P > ItI 
Intercept 1.084 0.071 < 0.0001 
Log Aurora A 0.457 0.033 < 0.0001 
Log Aurora B 0.268 0.031 < 0.0001 
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